Pharma Capital

Creso Pharma has a deal on the table

The halt will remain in place until Wednesday 22nd March 2017.
shutterstock_578045545_58cf0ca67c647.jpg
Creso is focused on medical cannabis

Creso Pharma (ASX:CPH) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Creso requested the halt pending details of a significant sales and distribution update regarding the company entering into a new region.

The halt will remain in place until the opening of trade on Wednesday 22nd March 2017, or earlier if an announcement is made to the market.

View full CPH profile

Creso Pharma Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.